CTC cluster in breast cancer: synergetic metastasis promotion mechanism and transformation path from platelet cloaking to leukocyte escort
Clinical and Translational Oncology · 2025
DOI: 10.1007/s12094-025-04150-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Oncology, 2025. Verfasst von Cangtai Guan und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Life Sciences, Jiangxi University of Traditional Chinese Medicine, Nanchang, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoplastic Cells, Circulating, Blood Platelets, Leukocytes. Die Arbeit nennt 73 Literaturangaben. Gefördert von: Natural Science Foundation of Jiangxi Province, Key Research and Development Program of Jiangxi Province.
Abstract (Originalsprache)
Circulating tumor cell (CTC) clusters are potent drivers of metastasis in breast cancer, and their survival and dissemination within the circulatory system are critically governed by dynamic interactions with the host microenvironment. Two key mechanisms-"platelet cloaking" and "leukocyte escort"-have emerged as central axes that amplify the metastatic potential of these clusters. This review synthesizes these parallel yet intersecting pathways, elucidates the biological basis for their synergistic interplay, and proposes a translational roadmap from mechanistic insight to clinical application. Accumulating evidence indicates that breast cancer CTC clusters originate from the oligoclonal shedding of primary tumor cells, with their structural integrity maintained by the intercellular adhesion molecule plakoglobin. Within the circulation, CTCs form heterogeneous clusters with neutrophils, a phenomenon strongly associated with poor patient prognosis that activates cell cycle programs, supporting the concept of "proliferation in transit". Concurrently, platelet cloaking, mediated by molecules such as P-selectin, confers multiple survival advantages: it shields clusters from hemodynamic shear stress, facilitates evasion of immune surveillance (notably NK cell-mediated cytotoxicity), and forms microthrombi that act as "docking scaffolds" to enhance extravasation efficiency. While the advent of low-shear microfluidic technologies now enables the precise isolation and functional characterization of these clusters, a significant gap persists in high-level clinical evidence for interventions. Preclinical studies have identified the selectin/integrin network and fibrinogen as highly promising therapeutic targets. Therefore, we propose the implementation of mechanism-driven, exploratory clinical trials guided by biomarkers (e.g., dynamic changes in CTC clusters) and conducted within the perioperative "window of opportunity" to validate the clinical feasibility and safety of therapeutically targeting this "platelet cloaking and leukocyte escort" axis in breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Life Sciences, Jiangxi University of Traditional Chinese Medicine, Nanchang, China.
- College of Life Sciences, Jiangxi University of Traditional Chinese Medicine, Nanchang, China. 2992699831@qq.com.
Förderung
- Natural Science Foundation of Jiangxi Province
- Key Research and Development Program of Jiangxi Province
Zitieren
APA
Guan, C., Hao, L., Gong, B., & Zheng, L. (2025). CTC cluster in breast cancer: synergetic metastasis promotion mechanism and transformation path from platelet cloaking to leukocyte escort. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-025-04150-2
Vancouver
Guan C, Hao L, Gong B, Zheng L. CTC cluster in breast cancer: synergetic metastasis promotion mechanism and transformation path from platelet cloaking to leukocyte escort. Clinical and Translational Oncology. 2025. doi:10.1007/s12094-025-04150-2
BibTeX
@article{Guan2025,
author = {Guan, Cangtai and Hao, Liangyu and Gong, Biyao and Zheng, Lixiang},
title = {CTC cluster in breast cancer: synergetic metastasis promotion mechanism and transformation path from platelet cloaking to leukocyte escort},
journal = {Clinical and Translational Oncology},
year = {2025},
doi = {10.1007/s12094-025-04150-2}
}
EUVIMED